CY1105276T1 - Τριφασικο στοματικο αντισυλληπτικο - Google Patents

Τριφασικο στοματικο αντισυλληπτικο

Info

Publication number
CY1105276T1
CY1105276T1 CY20061100638T CY061100638T CY1105276T1 CY 1105276 T1 CY1105276 T1 CY 1105276T1 CY 20061100638 T CY20061100638 T CY 20061100638T CY 061100638 T CY061100638 T CY 061100638T CY 1105276 T1 CY1105276 T1 CY 1105276T1
Authority
CY
Cyprus
Prior art keywords
estrogen
days
progestogen
norethindrone
administration
Prior art date
Application number
CY20061100638T
Other languages
English (en)
Inventor
Gary Shangold
Arkady Rubin
David Upmalis
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22349144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105276(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Publication of CY1105276T1 publication Critical patent/CY1105276T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Αποκαλύπτεται μια μέθοδος για αντισύλληψη στην οποία ένα οιστρογόνο και ένα προγεστογόνο χορηγούνται καθημερινά σε μια αλληλουχία τριών φάσεων για 21 μέρες. Στην πρώτη φάση ένας συνδυασμός ενός οιστρογόνου και ενός προγεστογόνου σε μια χαμηλή αλλά δραστική αντισυλληπτικά ημερήσια δόση που αντιστοιχεί σε οιστρογονική δραστηριότητα 23-28 μg της 17α-αιθυνιλοιστραδιόλης και σε προγεστογονική δραστηριότητα 0.065-0.75 νορεθινδρόνης χορηγείται για 5-8 ημέρες, ακολουθούμενη από την χορήγηση της ίδιας δόσης οιστρογόνου και προγεστογόνου που αντιστοιχεί σε προγεστογονική δραστηριότητα 0.25-1.0 μg νορεθινδρόνης για 7-11 ημέρες, ακολουθούμενη από την χορήγηση της ίδιας δόσης οιστρογόνου και προγεστογόνου που αντιστοιχεί σε προγεστογονική δραστηριότητα 0.35-2.0 μg νορεθινδρόνης για 3-7 ημέρες, ακολουθούμενη από 4-8 ημέρες χωρίς την χορήγηση ούτε οιστρογόνου ούτε προγεστογόνου.
CY20061100638T 1998-12-23 2006-05-17 Τριφασικο στοματικο αντισυλληπτικο CY1105276T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11339498P 1998-12-23 1998-12-23
PCT/US1999/029129 WO2000038691A1 (en) 1998-12-23 1999-12-08 Triphasic oral contraceptive

Publications (1)

Publication Number Publication Date
CY1105276T1 true CY1105276T1 (el) 2010-03-03

Family

ID=22349144

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100638T CY1105276T1 (el) 1998-12-23 2006-05-17 Τριφασικο στοματικο αντισυλληπτικο

Country Status (26)

Country Link
US (2) US6214815B1 (el)
EP (1) EP1140109B1 (el)
JP (1) JP2002533398A (el)
KR (1) KR100669165B1 (el)
CN (1) CN100408040C (el)
AR (1) AR028809A1 (el)
AT (1) ATE318605T1 (el)
AU (1) AU765153B2 (el)
BR (1) BR9916579A (el)
CA (1) CA2356747C (el)
CY (1) CY1105276T1 (el)
CZ (1) CZ302568B6 (el)
DE (1) DE69930157T2 (el)
DK (1) DK1140109T3 (el)
ES (1) ES2259481T3 (el)
HU (1) HU229251B1 (el)
MX (1) MXPA01006533A (el)
NO (1) NO321118B1 (el)
NZ (1) NZ512404A (el)
PL (1) PL196715B1 (el)
PT (1) PT1140109E (el)
RU (1) RU2225207C2 (el)
SK (1) SK287931B6 (el)
TR (1) TR200101826T2 (el)
WO (1) WO2000038691A1 (el)
ZA (1) ZA200106006B (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
HUP9900213A1 (hu) * 1999-02-01 2000-12-28 Gábor Bogye Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére
US20060281723A1 (en) * 1999-04-16 2006-12-14 Kafrissen Michael E Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US8048869B2 (en) * 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
PT1390042E (pt) * 2001-05-23 2008-03-10 Pantarhei Bioscience Bv Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal
US20040202713A1 (en) * 2001-05-23 2004-10-14 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
ATE449606T1 (de) * 2001-05-23 2009-12-15 Pantarhei Bioscience Bv Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
EP1446128B1 (en) * 2001-11-15 2006-12-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
EP2305230B1 (en) * 2001-12-05 2015-11-04 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy
CN1691947B (zh) * 2002-06-11 2011-11-23 潘塔希生物科学股份有限公司 雌激素成分在制备用于治疗或预防免疫介导的疾病中的应用以及包含所述雌激素成分的药物组合物
US7943604B2 (en) * 2002-06-11 2011-05-17 Pantarhei Bioscience B.V. Method of treating human skin and a skin care composition for use in such a method
ATE382356T1 (de) * 2002-07-12 2008-01-15 Pantarhei Bioscience Bv Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
JP2004140323A (ja) * 2002-08-20 2004-05-13 Sharp Corp 半導体レーザ装置およびその製造方法
DK1556058T3 (da) * 2002-10-23 2008-03-03 Pantarhei Bioscience Bv Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
US7772219B2 (en) 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
BRPI0412493A (pt) * 2003-07-16 2006-10-17 Duramed Pharmaceuticals Inc métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio
EP1673094A1 (en) * 2003-10-01 2006-06-28 Janssen Pharmaceutica N.V. Extended triphasic contraceptive regimens
DE102004026671A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
AR051931A1 (es) * 2004-10-07 2007-02-21 Duramed Pharmaceuticals Inc Metodos de tratamiento hormonal que utilizan regimenes de ciclos extendidos con dosis ascendentes
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070077269A1 (en) * 2005-10-04 2007-04-05 Woodward John R Method of birth control and hormone regulation
US20070254858A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
US20070254025A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Oral contraceptive and acne medication combination and treatment of acne with reduced side effects
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8236785B2 (en) * 2007-01-08 2012-08-07 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
DE102007011486A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
ES2795455T3 (es) 2008-10-08 2020-11-23 Agile Therapeutics Inc Suministro transdérmico
EP2343963B1 (en) 2008-10-08 2019-04-10 Agile Therapeutics, Inc. Transdermal delivery
US9198920B2 (en) 2009-03-27 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
CN107847506A (zh) 2015-06-22 2018-03-27 来普卡公司 含17‑羟基孕酮酯的口服组合物和相关方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3568828A (en) 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
US3836651A (en) 1972-02-22 1974-09-17 Biolog Concepts Inc Novel oral contraceptive combination
US3969502A (en) 1972-04-14 1976-07-13 Schering Aktiengesellschaft Method for contraception by the administration of sequential contraceptive preparations
DE2310963A1 (de) 1972-04-14 1974-09-05 Schering Ag Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten
US3932635A (en) 1972-04-24 1976-01-13 Syntex Corporation Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
DE2365103C3 (de) 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
US4291028A (en) 1977-12-30 1981-09-22 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
NL8001593A (nl) 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4390531A (en) 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
USRE35724E (en) 1982-04-28 1998-02-03 Bio-Technology General Corp. Contraception system and method
US4616006A (en) 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5276022A (en) 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US4948593A (en) 1989-05-15 1990-08-14 Alza Corporation Osmotic dosage form comprising an estrogen and a progestogen
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
US5453279A (en) 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5747480A (en) 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive

Also Published As

Publication number Publication date
AU1936500A (en) 2000-07-31
DE69930157T2 (de) 2006-08-31
HUP0104680A2 (hu) 2002-04-29
TR200101826T2 (tr) 2001-12-21
WO2000038691A1 (en) 2000-07-06
EP1140109B1 (en) 2006-03-01
KR20010081087A (ko) 2001-08-25
CN1334734A (zh) 2002-02-06
ATE318605T1 (de) 2006-03-15
CN100408040C (zh) 2008-08-06
PT1140109E (pt) 2006-05-31
NO20013144D0 (no) 2001-06-22
CA2356747C (en) 2005-09-27
US6214815B1 (en) 2001-04-10
US20010044429A1 (en) 2001-11-22
CZ20012184A3 (cs) 2003-01-15
AR028809A1 (es) 2003-05-28
NZ512404A (en) 2003-08-29
NO321118B1 (no) 2006-03-20
AU765153B2 (en) 2003-09-11
JP2002533398A (ja) 2002-10-08
PL196715B1 (pl) 2008-01-31
HUP0104680A3 (en) 2002-06-28
ZA200106006B (en) 2002-10-21
MXPA01006533A (es) 2002-06-04
RU2225207C2 (ru) 2004-03-10
CA2356747A1 (en) 2000-07-06
SK8872001A3 (en) 2002-03-05
HU229251B1 (en) 2013-10-28
EP1140109A1 (en) 2001-10-10
ES2259481T3 (es) 2006-10-01
CZ302568B6 (cs) 2011-07-13
DE69930157D1 (de) 2006-04-27
BR9916579A (pt) 2001-10-02
KR100669165B1 (ko) 2007-01-17
SK287931B6 (sk) 2012-04-03
NO20013144L (no) 2001-08-23
DK1140109T3 (da) 2006-05-15

Similar Documents

Publication Publication Date Title
CY1105276T1 (el) Τριφασικο στοματικο αντισυλληπτικο
LU90634I2 (fr) Gestodene et ethinylestradiol/minesse
DE69118494D1 (de) Kontrazeptionsverfahren und Schema
NL300381I2 (nl) Estradiolvaleraat en dienogest
BR9710566A (pt) M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
KR960704553A (ko) 적어도 하나의 프로게스토겐과 적어도 하나의 에스트로겐을 함유하는 대용요법용 제제(preparation for substitution therapy containing at least one progestogen and at least one estrogen)
WO1998004246A3 (en) Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
DK0917466T3 (da) Oralt antikonceptionsmiddel
AU4043597A (en) Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen
NO974255L (no) Preparat for injeksjon én gang pr. måned og som er anvendbart som depot-befruktningshemmende middel og i hormon-erstatningsterapi for perimenopausale og premenopausale kvinner